UCB : Ahead of its 2021 guidance, H2 21 focused on clinical developments
>A very solid H1 2021 - UCB has published a very good H1 2021, 3.5% above consensus forecasts for revenues and 4% above for underlying EBITDA, 10% above forecasts for EPS. Revenues were up 7% at constant forex driven by the persistently strong momentum on the group’s core products with Vimpat (+9% at cc), Cimzia (+11%) and Keppra (+23%). It is the sales of the latter that explain the main difference with expectations. Keppra was boosted notably by sales in Japan where...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.